Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Alternating or Combined Therapy With Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated, or Blastic Phases

NCT02782403 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02782403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02782403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Alternating or Combined Therapy With Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated, or Blastic Phases
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Terminated
Start date
March 20, 2017
Completion date
November 11, 2019
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

accelerated phase chronic myelogenous leukemia (cml), blast phase chronic myelogenous leukemia (cml), chronic phase phase chronic myelogenous leukemia (cml), philadelphia chromosome positive (ph+) phase chronic myelogenous leukemia (cml)